Sumitomo Pharma

Profil de la société

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Description disponible en anglais.

Informations sur la société

Secteur

Santé

Industrie

Drug Manufacturers - Specialty & Generic

Pays

Japon

Siège

2-6-8 Doshomachi, 541-0045, Osaka

Cotation

4506 · TSE

Indices

Nikkei 225

Devise

JPY

ISIN

JP3495000006

Site web

sumitomo-pharma.com